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Numerous studies concerning the health-
related effects of environmental toxicants
demonstrate that the immune system, in addi-
tion to other organ systems including the
reproductive, nervous, pulmonary, and circula-
tory systems, is often compromised (Carpy
et al. 2000; Costa 1997). Our understanding of
such adverse immunologic effects, however, is
largely limited to the immediate and early con-
sequences after exposure to such agents. The
principal contribution of this present article to
the field of immunotoxicology research is its
demonstration that the potential long-term
impact of propanil (PRN) exposure on cell-
mediated immunity is far more severe than its
short-term consequences. This delayed appear-
ance of irreversible PRN-induced immunotoxic
effects may be important for diagnostic and
therapeutic measures in assessing exposure to
environmental toxicants in general.
PRN is a postemergent herbicide used
extensively around the world in the cultivation
of rice and wheat crops. Its particular effective-
ness is due to the high level of acylamidase
expression in a rice plant that allows it to
detoxify PRN, whereas common grass-type
weeds lack this enzyme and are killed by this
herbicide (Matsunaka 1968). PRN is routinely
applied several times during a growing season
without detrimental effects to the plant
(Casida and Lykken 1969; Smith 1961), with
3–6 lb/acre applied annually in the United
States (Costa 1997; Matsunaka 1968). Thus, a
high environmental exposure of humans to
PRN normally occurs as an occupational risk.
Earlier reports by Barnett and co-workers
(Barnett et al. 1992; Barnett and Gandy 1989;
Frost et al. 2001; Theus et al. 1993; Xie et al.
1997; Zhao et al. 1995, 1998) indicated that
PRN exposure results in adverse effects on
most compartments of the immune system,
including macrophages, B lymphocytes, and
T-helper lymphocytes. Curiously, however,
there appeared to be little, if any, effect on 
cellular immunity mediated by cytotoxic
T-lymphocyte (CTL) effectors (Barnett et al.
1992; Barnett and Gandy 1989).
Given that the responsiveness of the other
immune compartments examined is inhibited
by PRN exposure, we hypothesized that acute
PRN exposure might yet impair CTL func-
tion, albeit in a manner that is initially difficult
to detect under the in vitro conditions used.
To test this hypothesis we considered that the
adverse immunotoxic effects of PRN exposure
on cell-mediated immunity might be observed
in one or more of three parameters: a) presen-
tation of peptide antigen to CTLs by antigen-
presenting cells (APCs), b) proliferation and
differentiation of CTLs, and/or c) functional
lytic response of activated CTL effectors.
The immune activation and functional
responsiveness of CTLs can be examined and
assessed independently in vitro. CTL activation
is based on the capacity of APCs to efficiently
process and present peptide antigens to CTLs
and thus indirectly affects CTL responsiveness.
Conversely, the functional lytic response of
CTLs emerges as a result of the differentiation
of naive CD8+ T cells into effector CTLs capa-
ble of responding through lysis of the target
cell, thereby serving as a direct measure of
CTL activation.
In this present article, we demonstrate
three important consequences of PRN expo-
sure on the in vitro parameters of CTL activa-
tion and their functional activity as effectors
of cell-mediated immunity: a) antigen presen-
tation to CTLs is not impaired, b) the func-
tional lytic activity of primary (1°) CTLs is
only marginally impaired, and c) upon restim-
ulation of 1° CTLs in the absence of PRN,
the secondary (2°) CTL response is com-
pletely abrogated. On the basis of these obser-
vations, we conclude that the immunotoxic
effects of PRN exposure on CTLs are delayed
in their appearance and directly impair the
functional activity of these effectors of cell-
mediated immunity. These results may have
serious and important direct implications for
both diagnosis and clinical management of the
acute and chronic effects of PRN exposure.
Furthermore, these findings warrant examin-
ing similar acute versus delayed exposure
effects with respect to the immunotoxic
potential of other environmental toxicants.
Materials and Methods
Animals. In this study we used C57BL/6 (B6;
H-2b) and BALB/c (H-2d) female mice
10–12 weeks of age from Charles River
Breeding Laboratories, Inc. (Wilmington,
MA) or from our own breeding colony at the
West Virginia University Health Sciences
Vivarium. All animals used in this study
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The postemergent herbicide propanil (PRN; also known as 3,4-dichloropropionanilide) is used on
rice and wheat crops and has well-known immunotoxic effects on various compartments of the
immune system, including T-helper lymphocytes, B lymphocytes, and macrophages. It is unclear,
however, whether PRN also adversely affects cytotoxic T lymphocytes (CTLs), the primary (1°)
effectors of cell-mediated immunity. In this study we examined both the direct and indirect effects
of PRN exposure on CTL activation and effector cell function to gauge its likely impact on cell-
mediated immunity. Initial experiments addressed whether PRN alters the class I major histo-
compatibility complex (MHC) pathway for antigen processing and presentation by
antigen-presenting cells (APCs), thereby indirectly affecting effector function. These experiments
demonstrated that PRN does not impair the activation of CTLs by PRN-treated APCs. Subsequent
experiments addressed whether PRN treatment of CTLs directly inhibits their activation and
revealed that 1° alloreactive CTLs exposed to PRN are unimpaired in their proliferative response
and only marginally inhibited in their lytic activity. Surprisingly, secondary stimulation of these
alloreactive CTL effectors, however, even in the absence of further PRN exposure, resulted in com-
plete abrogation of CTL lytic function and a delayed but significant long-term effect on CTL
responsiveness. These findings may have important implications for the diagnosis and clinical man-
agement of anomalies of cell-mediated immunity resulting from environmental exposure to various
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were treated humanely and with regard for
alleviation of suffering.
Cell lines. Two tumor cell lines, designated
P815 (H-2d) and EL4 (H-2b), were used as tar-
gets for alloreactive cytotoxic T cells. The EL4
cell line expresses class I H-2b molecules and is
derived from a B6 lymphoma originally
induced in a C57BL/6N mouse by 9,10-
dimethyl-1,2-benzanthracene (Gorer 1950).
P815 is a cell line derived from a mastocytoma
in DBA/2 (H-2d) mice, and it expresses class I
H-2d molecules (Plaut et al. 1973; Ralph and
Nakoinz 1974). Both the EL4 and P815 cell
lines have been used extensively by us and oth-
ers as suitable targets for lysis in cytotoxic
T-cell assays. N1 is derived from EL4 cells
transfected with the vesicular stomatitis virus
nucleoprotein (VSB-N) gene (Puddington
et al. 1986).
Monoclonal antibodies and fluorescence
activated cell sorting analysis. We used the fol-
lowing H-2Kb-specific monoclonal antibodies
(mAb): 5F1 (Sherman and Randolph 1981),
Y-3 (Jones and Janeway 1981), EH144
(Bluestone et al. 1985; Geier et al. 1986), Y-25
(Jones and Janeway 1981), and 28-13-3 (Ozato
and Sachs 1981). Fluorescein isothiocyanate
goat anti-mouse immunoglobulin (heavy- and
light-chain–specific) was purchased from
Southern Biotechnology Associates, Inc.
(Birmingham, AL).
Citric acid treatment of APCs. The acid
treatment protocol used in these studies to
strip the APC cell surfaces of class I peptide/
major histocompatibility complex (pMHC)
complexes is essentially the same as that
described by Sugawara et al. (1987), as modi-
fied by Storkus et al. (1993). Briefly, APCs are
a) collected and pelleted by centrifugation;
b) resuspended in 0.5 mL citrate-phosphate
buffer, pH 3.0 (citrate-phosphate buffer con-
sists of a 1:1 mixture of 0.263 M citric acid,
pH 1.8, and 0.123 M Na2HPO4); c) incu-
bated in citrate-phosphate buffer for 1 min at
room temperature; d) resuspended in 10 mL
RP-10 media, pelleted, and washed with
Hank’s balanced salt solution; and e) resus-
pended to appropriate concentration in RP-10
media. RP-10 tissue culture media consists of
RPMI-1640 media plus 10% fetal calf serum,
with supplemental vitamins, nonessential
amino acids, and HEPES buffer.
Effector cells. VSV-N peptide–specific
CTLs were maintained in vitro by weekly
stimulation with the target VSV-N peptide,
p52-59. Briefly, 4 × 105 CTL clone 33 cells
were incubated in a 24-well flat-bottom plate
with 5 × 106 irradiated (2,000 rads) B6 spleen
cells plus 2 μM VSV-N p52-59 peptide sus-
pended in RP-10 media. CTL clone 33 cells
were analyzed for antigen-specific lytic reactiv-
ity with 51Cr-labeled N1 transfectant targets
on day 5 and subsequently restimulated on
day 7 of culture.
Alloreactive CTLs were induced by 1°
stimulation of B6 spleen cells with irradiated
(2,000 rads) spleen cells from BALB/c mice.
Briefly, spleens were removed and processed
into single-cell suspension preparations;
BALB/c spleen cell suspensions were irradiated
in a Gammacell 1000 cesium-137 irradiator
(Atomic Energy of Canada Ltd., Kanata,
Ontario, Canada) to deliver 2,000 rads. For 1°
alloreactive stimulation, 25 × 106 B6 spleen
cells per flask were added to upright T-25
flasks with 25 × 106 BALB/c irradiated spleen
cells in 10 mL RP-10 media. Alloreactive cul-
tures were placed in a 37°C humidified incuba-
tor at 7% CO2 for 7 days.
Secondary alloreactive cultures were pre-
pared similarly in RP-10 media except that
2.5 × 106 1° effectors per flask were added
together with 25 × 106 irradiated BALB/c
spleen cells to upright T-25 flasks. Cultures
were incubated for 7 days in the same manner
as the 1° alloreactive cultures. Subsequent cul-
tures beyond the 2° alloreactive effectors were
maintained in 24-well dishes (Corning-
Costar; Corning Life Sciences, Corning NY,)
by the addition of 1 × 105 effectors plus 1 ×
106 irradiated BALB/c spleen cells per well in
2 mL RP-10 media supplemented with 5%
rat concanavalin A supernatant as a source of
interleukin-2.
Mixed lymphocyte reaction assay. To
measure the extent of alloreactive T-cell stim-
ulation in mixed lymphocyte cultures (MLCs)
and the effect of adding PRN on the induc-
tion of alloreactive CTL effectors, we used the
mixed lymphocyte reaction (MLR) assay, as
previously described (Sheil et al. 1987). T-cell
proliferation was determined in a one-way
MLR assay on day 4 of culture by the incor-
poration of tritiated thymidine (3H-TdR) by
proliferating T cells. Briefly, after 72 hr of cul-
ture, 5 × 105 viable 1° MLC cells in 100 μL
plus 1 μCi 3H-TdR in 100 μL RP-10 were
added per well to four wells per sample in a
96-well plate (Corning-Costar; Corning Life
Sciences). After incubation for 18–24 hr at
37°C in a 7% CO2 humidified incubator, the
cells were harvested, and the amount of prolif-
eration was determined by measuring 3H-TdR
uptake, as reflected by the total radioactive
counts per sample in liquid scintillation fluid.
51Cr-release assay. We determined the lytic
activity of peptide-specific and alloreactive
effector CTLs using a standard 4-hr in vitro
51Cr-release assay, as previously described (Sheil
et al. 1987). Briefly, tumor cells to be used as
targets were labeled with radioactive sodium
chromate (Na51Cr) and mixed with titrated
doses of peptide-specific or alloreactive CTLs in
200 μL RP-10/well in 96-well round-bottom
microtiter plates (Costar-Corning; Corning Life
Sciences). The plates were incubated at 37°C in
7% CO2 for 4 hr and centrifuged, and 100 μL
supernatant was collected from each well. The
amount of specific lysis was determined accord-
ing to the following formula: % specific lysis =
(experimental release – spontaneous release) ÷
(maximum release – spontaneous release) × 100. 
PRN exposure. PRN (3,4-dichloroproprio-
naniline; > 97% purity) was purchased from
Chem Service, Inc. (West Chester, PA) and
dissolved in 70% ethanol (EtOH). Exposure of
alloreactive effectors to PRN in vitro was
accomplished by the addition of PRN concen-
trations of 16, 33, or 66 μM to the culture
media at the initiation of culture (day 0) for
1° MLCs; for 2° MLCs, the PRN concentra-
tions used were 66 and 165 μM. PRN
remained in the media for the duration of the
culture incubation period—usually 7 days.
APCs and target cells were exposed in vitro to
PRN (200 μM) for a period of either 18 hr or
2 hr at 37°C in 7% CO2, after which the PRN
is washed out of the cultures.
Statistical analysis. All results shown
are representative of at least three repeated
experiments, and the sample points in each
experiment were run in triplicate. Thus, we
performed all statistical analyses using triplicate
samples for data points within each experi-
ment. Statistical evaluation was conducted
using the Student’s t-test analysis, and signifi-
cance in observed differences as described in
the text was established as being at a level of
p ≤ 0.01.
Results
To determine how PRN exposure might
adversely affect cell-mediated immunity, we
designed the initial experiments of this study
to address its potential impact both indirectly
(on in vitro antigen presentation to CTLs) and
directly (on CTL lytic function). We first con-
sidered the requirement that antigen-specific
CTLs must respond to a peptide antigen
exposed on the surface of APCs bound to a
self class I MHC molecule. If there is an
adverse indirect effect on cell-mediated immu-
nity due to PRN exposure, it could result
from altered antigen processing and presenta-
tion characteristics of the APC. Alternatively,
the exposure of potential effector CTLs to
PRN might directly interfere with CTL prolif-
eration and/or effector function. To address
whether PRN exposure has a discernible effect
on antigen presentation, we examined the
well-characterized CTL response to the single
antigenic peptide, VSV-N p52-59, in the con-
text of the class I H-2Kb molecule (Sheil et al.
1987; Van Bleek and Nathenson 1990). To
examine the possible direct effects on CTL
proliferation and/or differentiation, B6 anti-
BALB/c MLC-derived CTLs were used as
alloreactive effectors.
PRN-exposed APCs are recognized effi-
ciently by VSV-N peptide–specific CTLs. We
examined the functional capacity of PRN-
exposed APCs to determine whether PRN
Sheil et al.
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exposure of APCs in vitro adversely affects their
ability to process and/or present antigen in the
class I MHC pathway. The VSV-N transfec-
tant model system (Puddington et al. 1986)
was used, as described previously (Sheil et al.
1987), to determine whether exposure of VSV-
infected cells to PRN interferes with their abil-
ity to effectively present viral peptide antigens
to CTLs. In these experiments, CTL clone 33,
specific for VSV-N p52-59 (Sheil et al. 1987),
was tested against the target VSV-N trans-
fected EL4 (H-2b) tumor cell line, designated
N1. Initially, N1 cells were exposed to PRN
for 18 hr before their use as CTL targets; how-
ever, because of undesirable levels of toxicity to
the N1 cells (i.e., up to 30%), the period of
incubation with PRN was decreased to 2 hr.
After incubation in the presence of PRN for
either 2 or 18 hr, N1 cells were tested as targets
for lysis by clone 33. The results depicted in
Figure 1 demonstrate that incubation of N1
cells with PRN does not adversely affect their
capacity to serve as targets for lysis by VSV-N
peptide–specific CTL effectors.
Another possible effect of PRN is its inter-
ference with the ability of N1 cells to serve as
stimulators for the induction of VSV-N
peptide–specific CTL effectors, even though
they are undiminished in their capacity to serve
as targets for CTL lysis. To address this possi-
bility, we used N1 cells as APC stimulators for
the VSV-N p52-59 peptide–specific, H-2Kb-
restricted CTL clone 33. After a 2-hr exposure
to 200 μM PRN, N1 cells were added to cul-
ture flasks as stimulators for clone 33 CTLs.
The 4-hr 51Cr-release assay results depicted in
Figure 2 demonstrate that PRN-treated N1
cells are effective stimulators, in that they are
undiminished, compared with control EtOH-
treated N1 cells, in their capacity to stimulate
lytic activity in clone 33 CTLs. This conclu-
sion is reinforced by the observation that cell
viability (as determined by trypan blue dye
exclusion) and proliferative capacity (as deter-
mined by 3H-TdR uptake in the MLR assay)
of clone 33 CTLs are not significantly different
after culture with either control EtOH-treated
or PRN-exposed N1 cells (data not shown).
Citric acid–treated EL4 cells are recognized
efficiently by VSV-N peptide–specific CTLs
after PRN exposure. Previous studies have
demonstrated that a CTL effector requires only
very few pMHC complexes on the surface of an
APC to become activated by and lyse the APC
as its target (Brower et al. 1994; Christinck
et al. 1991). Thus, the ability of PRN-treated
N1 cells to efficiently present antigen to CTLs
and to serve as targets for lysis may correspond
to their expression of this minimal number of
pMHC complexes needed to target CTL lysis,
even though it may be much lower than is nor-
mally expressed on N1 cells not exposed to
PRN. To address this possibility, we subjected
EL4 cells (from which the N1 cell line is
derived) to citric acid treatment, an approach
that strips most pMHC complexes from the
cell surface (Storkus et al. 1993; Sugawara et al.
1987). As shown in Table 1, treatment of EL4
cells in this manner results in a similarly dra-
matic decrease in MHC class I expression,
regardless of their subsequent exposure to PRN.
This decreased MHC class I expression, how-
ever, does not adversely affect the presentation
of peptide antigen to VSV-N peptide–specific
CTLs, as shown by their undiminished lysis of
acid-treated EL4 targets either with or without
PRN exposure (Figure 3). Note that the exquis-
ite sensitivity of this peptide-specific lysis is
unaffected even with the addition of a concen-
tration of target peptide as low as 78 pM. These
results clearly indicate that the class I MHC
antigen presentation pathway after PRN expo-
sure, under these conditions, remains intact and
fully functional.
Primary alloreactive CTLs show limited
inhibition after PRN exposure. Given that we
observed no overt adverse effects of PRN expo-
sure on APC function, we directed our atten-
tion to whether PRN exposure interferes
directly with CTL function itself. To address
this point, an alloreactive C57BL/6 (B6) anti-
BALB/c mouse model system, as described in
“Materials and Methods,” was used to obtain
CTL effectors. The effect of PRN exposure on
alloreactive CTL activation was examined in
two ways. First, we measured the proliferative
capacity of BALB/c-stimulated B6 CTLs in a
standard 3H-TdR uptake assay. Second, to
detect any functional changes in CTL effector
activity, we measured allospecific CTL lysis of
P815 targets in an in vitro 4-hr 51Cr-release
assay (Sheil et al. 1987).
The in vitro PRN-exposed 1° B6 anti-
BALB/c CTLs are unchanged in their prolifer-
ative capacity compared with EtOH-treated
control CTLs (Figure 4A), thereby indicating
that there is no effect on their ability to prolif-
erate in response to antigen stimulation after
exposure to a range (16, 33, or 66 μM) of
PRN concentrations. Furthermore, their func-
tional lytic reactivity is only marginally inhib-
ited after PRN exposure, and only at the
highest (66 μM) concentration used in these
experiments, as shown by the CTL lytic
response in a 4 hr in vitro 51Cr-release assay
(Figure 4B).
Proliferation and reactivity of secondary
CTLs are markedly impaired after PRN expo-
sure. We next addressed whether the subse-
quent in vitro exposure of these alloreactive
CTLs to PRN, during their 2° stimulation,
might reveal an increased adverse effect on CTL
proliferation and/or CTL lytic activity. To
Delayed inhibition of CTL activation by propanil
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Figure 1. CTL clone 33 lytic response in a 4-hr 51Cr-
release assay against N1 targets: EtOH treated,
exposed to PRN for 18 hr, or exposed to PRN for
2 hr.  The x-axis indicates the ratio of effector T cells
per target cell added to each well in the 51Cr-release
assay; ratios range from 30:1 to 0.1:1.
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Figure 2. Clone 33 stimulated with EtOH-treated N1 (A) or PRN-treated N1 (B) stimulators, tested against
N1 targets: EtOH treated, exposed to PRN for 18 hr, or exposed to PRN for 2 hr. Results shown are repre-
sentative of three experiments; all sample points were run in triplicate. Effector:target ratios range from
30:1 to 0.1:1.
Table 1. H-2Kb expression on acid-treated EL4 cells: mean channel fluorescence (MCF).
No antibody Y-3 mAb (anti-Kb) Anti-Kb mAb mix
Cell treatment MCF Ratio MCF Ratio MCF Ratio
EtOH-treated EL4 2 — 56 1.0 61 1.0
Acid-treated EL4 3 — 31 0.52 37 0.58
Acid-treated EL4 + 1 hr at 37°C 2 — 31 0.54 35 0.56
Acid-treated EL4 + PRN exposed 2 — 38 0.67 37 0.59
examine this possibility, 1° alloreactive CTLs
were harvested on day 7 of culture, washed, and
restimulated with the addition of fresh PRN as
described in “Materials and Methods.”
In the same manner as with alloreactive
CTLs from 1° MLCs, we tested 2° alloreac-
tive CTLs for their proliferative capacity
(Figure 5A) and their lytic responsiveness
(Figure 5B). Secondary B6 anti-BALB/c MLCs
were exposed to 66 or 165 μM PRN during
in vitro 2° stimulation. Because we saw no
effects at the lower PRN concentrations of 16
and 33 μM in 1° MLCs, they were excluded
from further analysis with 2° CTLs. Instead, 2°
MLCs were set up using the effective 66 μM
PRN concentration, as well as a higher concen-
tration of 165 μM.
We tested secondary CTLs on day 4 for
proliferation (Figure 5A) and on day 5 for lytic
activity against syngeneic P815 targets
(Figure 5B). We included an important control
group in which PRN-exposed 1° MLC effec-
tors were washed and restimulated in 2° MLCs
without additional exposure to PRN. As shown
in Figure 5A, the proliferative capacity of the
1° EtOH-treated/2° 66 μM PRN group (sec-
ond bar) is fully intact, whereas the 1° EtOH-
treated/165-μM PRN group (third bar) shows
no proliferative capacity above background (i.e.,
media control). Interestingly, for the lytic
response of the 1° EtOH-treated/2° 66-μM
PRN group (Figure 5B, left), the level of inhi-
bition also is approximately double that seen
with CTLs exposed to 66 μM PRN in
1° MLC (Figure 4B). On the basis of this
observation, we are presently examining
whether activated CTLs in 2° MLC might be
more susceptible to PRN-mediated inhibition
than are naive CD8+ T cells. 
It is unlikely that the unresponsiveness
observed in these groups is due to a generalized
PRN-induced toxicity to the exposed CTLs
because the viable cell yield of the 1° EtOH-
treated/165-μM PRN group is approximately
70% of the EtOH-treated group, and that of
the 1° EtOH-treated/2° 66-μM effectors is
approximately 90% that of the EtOH-treated
group. Furthermore, even the marginal decrease
in cell viability observed in these groups has
been taken into account in determining the
total number of viable cells used in both the
MLR and 51Cr-release assays. Cell populations
used in both assays were equalized based on
these total viable cell determinations; thus, the
number of cells added is the same for each
group. It is possible, however, that these cell
viability determinations do not take into
account damaged cells whose cell membranes
are still intact because these cells would exclude
the trypan blue dye until such point as
membrane damage has occurred.
Another important, although initially
unanticipated, finding concerns the control
alloreactive CTLs in the 1° 66-μM PRN/
2°-EtOH–treated group. These CTLs were
initially exposed to 66 μM PRN during
1° stimulation, followed by restimulation in
2° MLC in the absence of PRN. The lytic
activity of this group is almost completely
ablated (Figure 5B, middle), even though the
1° response is only marginally inhibited com-
pared with EtOH-treated 1° alloreactive CTLs
(Figure 4B). Thus, the CTL lytic response of
this group is nearly 20-fold lower in than that
of 66 μM PRN-treated 1° CTLs.
To determine whether this unanticipated
decline in CTL reactivity is irreversible,
3° MLCs were established without the addition
of PRN as was done for the 2° MLCs. So, in
this case we have alloreactive CTLs that have
been activated multiple times, but they were
exposed to PRN only during their initial activa-
tion. Among the 3° MLC-derived CTL effec-
tors, both proliferation and lytic activity
remained severely diminished (data not shown),
as seen with the 2° CTLs. Thus, the profound
PRN-induced defect incurred during their
1° MLC stimulation appears to render these
CTLs irreversibly impaired.
Discussion
Most herbicides and other pesticides exert a
diverse array of immunotoxic effects on
exposed individuals, including compromised
humoral and cellular immunity (Banerjee et al.
1996; Rodgers 1995; Vial et al. 1996; Voccia
et al. 1999). Earlier studies on the immuno-
toxic effects of PRN exposure by Barnett and
co-workers (Barnett et al. 1992; Barnett and
Gandy 1989) indicate that, although other
important immune parameters are adversely
diminished, the immunotoxic effects of PRN
Sheil et al.
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do not include impairment of cell-mediated
immunity. This apparent anomaly in the
immunotoxic impact of PRN exposure on dif-
ferent immune compartments prompted us to
consider whether the effects of PRN on cell-
mediated immunity might be more subtle or
less easily detectable than effects on other
immune compartments.
In the present study, we addressed the
immunotoxic potential of the herbicide PRN
on the effector cells of cell-mediated immunity,
CTLs. A rigorous in vitro analysis of CTL acti-
vation and function was applied to determine
whether and how PRN might induce immuno-
toxic effects in this regard. We approached this
problem with the understanding that impaired
cell-mediated immunity can result from
the inhibition in antigen presentation to
CD8+ T cells and/or, more directly, from a
diminished functional CTL response.
Antigen processing and presentation defects
have been implicated as the basis for impaired
cell-mediated immunity induced by viruses
(Fruh et al. 1997; Hewitt and Dugan 2004;
Mylin et al. 1995) and by antioxidants (Gong
and Chen 2003; Preynat-Seauve et al. 2003), as
well as in tumor development (Bennink et al.
1993; Cohen et al. 2003; Restifo et al. 1993;
Seliger et al. 1998) and aging (Plowden et al.
2004). The indirect consequences of these
agents on antigen presentation can adversely
affect the proliferation, differentiation, and
effector functions of T lymphocytes—including
cell signaling mechanisms, cytokine secretion,
developmental maturation, and target cell lysis
by CD8+ CTLs.
Thus it was important to examine the indi-
rect immunotoxic effects of PRN exposure on
the antigen processing and presentation com-
ponent of cell-mediated immunity. In addi-
tion, the most common direct measures of
CTL activation are proliferation and lytic activ-
ity. The experiments conducted in this study
incorporate both indirect and direct approaches
to determining the immunotoxic effects of
PRN exposure on antigen presentation and
CTL activation.
The most important findings of this study
are that a) exposure to PRN during 1° CTL
activation results in a dramatic delayed abro-
gation of CTL lysis that is irreversible, and
b) the immunotoxic effects of PRN exposure
under these conditions are limited to the func-
tional activity of CTLs and do not affect anti-
gen processing and presentation to CTLs.
This study is unique in that it demonstrates
such a striking difference between the short-
term and delayed appearance of the immuno-
toxic effects of this herbicide. The issue of
potentially delayed immunotoxic effects of
pesticides has not been a focus of most studies,
although some changes have been reported
after in utero exposure that manifested after
development (Colosio et al. 1999; Vial et al.
1996). This study, however, relates directly to
the impaired activation of mature effectors of
cell-mediated immunity. It is also important
that these effects impair the proliferation and
lytic activity of CTLs without interfering with
the presentation of antigen by APCs.
In the initial approach to address whether
PRN exposure inhibits cell-mediated immu-
nity, we examined its possible impact on anti-
gen processing and presentation in the class I
MHC antigen presentation pathway, and indi-
rectly on CTL induction and responsiveness.
This approach used VSV-N gene-transfected
N1 cells treated with PRN as targets for CTL-
mediated lysis by CTL clone 33 (Sheil et al.
1987), which is H-2Kb restricted and specific
for the VSV-N p52-59 peptide. Results
depicted in Figures 1 and 2 reveal that expo-
sure of APCs to PRN does not interfere with
their ability to target CTL-mediated lysis in an
antigen-specific manner. Nevertheless, it is
possible that PRN could adversely affect the
ability of APCs to effectively stimulate CTLs in
culture. The results depicted in Figure 2
demonstrate that the responses between
clone 33 CTLs stimulated with EtOH-treated
(Figure 2A) or PRN-exposed (Figure 2B) N1
cells are similar in their responsiveness to N1
targets, indicating that PRN exposure also does
not interfere with antigen presentation in a
stimulatory capacity. Thus, the antigen presen-
tation characteristics of N1 cells both as stimu-
lators and as targets for clone 33 CTLs are
unaltered by PRN exposure.
The absence thus far of any adverse effects
of PRN exposure on antigen presentation,
however, could be misleading because of the
large number of potential pMHC complexes
on N1 cells that can be engaged by the clone 33
T-cell receptors (TCRs). Previous studies
have shown that minimally approximately
50–200 pMHC complexes need to be engaged
for a CTL effector to lyse its target (Christinck
et al. 1991; Sykulev et al. 1994); it is likely that
many more pMHC complexes are formed and
available for engagement by the clone 33 TCR
on the N1 cells. Thus, if PRN exposure only
partially interferes with antigen processing or
presentation, its adverse effect may be masked
under these in vitro assay conditions. To cir-
cumvent this problem, we replaced N1 cells as
targets in the CTL lysis assay with untrans-
fected EL4 cells plus titrated amounts of the
target peptide VSV-N p52-59 (Figure 3). With
the addition of lower peptide concentrations
during this titration assay, fewer pMHC com-
plexes will be formed. If there is a defect in anti-
gen presentation, it should become apparent at
the lower peptide concentrations.
As shown in Figure 3, we observed signifi-
cant lysis even when a peptide concentration
as low as 7.8 pM is added to EL4 targets, yet
there is no significant difference in the level of
activity in PRN-exposed groups compared
with the EtOH-treated control group. With
the higher concentrations of added peptide
(up to 32 μM), the apparent difference
between EtOH-treated and PRN-exposed
EL4 targets is not significant. And even so, the
critical point to be made is that at lower con-
centrations with fewer surface pMHC com-
plexes formed, the sensitivity of the assay is
much greater, and at peptide concentrations
< 125 pM, the experimental and control
groups are virtually indistinguishable
(Figure 3). Thus, there is no observable effect
of PRN exposure on in vitro antigen presenta-
tion, and we concluded that APCs exposed to
PRN are unimpaired in their ability to serve
both as stimulators and as targets for peptide-
specific CTLs.
In the next phase of our study, we
addressed whether there is a direct effect of
PRN exposure on CTL reactivity alone. One
potential complication with the peptide-spe-
cific CTL model system is that when peptide is
added to in vitro cultures, it can bind to MHC
molecules expressed on the surface of CTLs
themselves as well as to those on the APCs,
thereby complicating the interpretation of
experimental results. To circumvent this prob-
lem we used an alloreactive B6 anti-BALB/c
MLC model system to examine the effect of
PRN on CTL proliferation and function.
In this model the alloreactive B6 CTLs
respond directly to the allogeneic class I MHC
molecules expressed on the BALB/c stimulator
cells without the need for added peptide. As
shown in Figure 4B, alloreactive CTLs exposed
to PRN during 1° MLC are largely unaffected
in their lytic reactivity, with only a limited
decrease in reactivity observed at the highest
(66 μM) concentration tested. Although there
is a 2.5-fold difference between the response of
the 66 μM PRN-exposed group and control
CTLs, given the similarities in magnitude of
their overall response, this apparent difference
is probably minimal. We also noted the con-
comitant observation that the proliferative
responses, as measured by 3H-TdR uptake in
the in vitro MLR assay, among all three PRN
exposure groups are not significantly different
from the EtOH control group (Figure 4A).
These findings are similar to those reported
initially by Barnett and co-workers (Barnett
et al. 1992; Barnett and Gandy 1989) and
seem to support their suggestion that PRN
might have very little, if any, effect on cell-
mediated immunity.
We next examined the impact of pro-
longed PRN exposure on these alloreactive
CTL effectors by adding fresh PRN during
their restimulation in 2° in vitro MLCs. The
overall effect of this longer-term exposure to
PRN is the appearance of a significantly
increased adverse effect on both CTL prolifera-
tion and lytic activity. Although PRN exposure
during 1° MLC activation has only a limited
Delayed inhibition of CTL activation by propanil
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effect on these parameters, the subsequent
exposure to PRN during 2° MLC activation
has a much greater adverse effect on CTL
effectors. Thus, the exposure of 2° MLC-
derived CTLs to 66 μM PRN induced an
almost 70-fold greater inhibition than the same
PRN concentration used in 1° MLCs. This
finding establishes the importance of long-term
symptoms in the diagnosis and management of
immunotoxic effects resulting from exposure
to environmental contaminants, particularly
with respect to repeated or chronic exposure
over an extended time period.
Even more striking is the nearly complete
abrogation of CTL function of 2° CTLs that
were exposed to PRN in the 1° MLC but not
to additional PRN upon 2° stimulation. The
nearly 8-fold difference in proliferation plus
greater than 20-fold difference in lytic activity
upon restimulation of PRN-exposed 1° CTLs
into 2° CTL effectors indicates that some early
PRN-induced adverse event(s) must have
occurred during 1° activation that has a greater
long-term functional impact on cell-mediated
immunity. Thus, the studies reported here
highlight the dramatic differences between
acute and chronic exposure effects as an impor-
tant consideration when assessing the
immunotoxic potential of environmental
agents. This often-neglected yet clinically
important parameter could have significant
diagnostic and treatment ramifications for the
detection and management of pathologic
anomalies associated with exposure to environ-
mental contaminants. It is also worth noting
that the delayed appearance of immunotoxic
effects after PRN exposure in the 1° MLC
might provide insight into questions of envi-
ronmentally relevant doses or concentrations
used in studies of various toxicants. This find-
ing suggests that the lack of observable toxic
effects might be due to a delayed onset in the
appearance of such effects rather than to the
administration of an inadequate toxic dose.
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